Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer. - Saorin G; Mauceri M; Caligiuri I; Kamensek U; Kranjc Brezar S; Corona G; Repetto O; Perin T; Grassi G; Granchi C; Tuccinardi T; Cemazar M; et al. (Cancer letters, 2026)